Perspectives on the PQRI Extractables and Leachables “Safety Thresholds and Best Practices” Recommendations for Inhalation Drug Products

References

1. 1.↵
   1. Stolarski R. S.,
   2. Cicerone R. J.

   Stratospheric chlorine: a possible sink for ozone. Can. J. Chem. 1974, 52, 1610–1615.

   OpenUrlCrossRefWeb of Science
2. 2.↵
   International Pharmaceutical Aerosol Consortium. Ensuring Patient Care—The Role of the HFC MDI, 2nd ed.; International Pharmaceutical Aerosol Consortium, 1999.
3. 3.↵
   1. Leach C. L.

   The CFC to HFA transition and its impact on pulmonary drug development. Respiratory Care 2005, 50 (9), 1201–1208.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Molina M. J.,
   2. Rowland F. S.

   Stratospheric sink for chlorofluoromethanes: chlorine atom-catalyzed destruction of ozone. Nature 1974, 249, 810–812.

   OpenUrlCrossRefWeb of Science
5. 5.↵
   1. Hansen G. E.

   Significance of leachables and extractables to pharmaceutical quality. presented at the PQRI Workshop on Safety Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products, Bethesda, MD, 2011.
6. 6.↵
   1. Ball. D. J.,
   2. Norwood D. L.,
   3. Nagao L. M.

   Overview of Leachables and Extractables in Orally Inhaled and Nasal Drug Products. In Leachables and Extractables Handbook; John Wiley and Sons, Inc.: Hoboken, NJ, 2012; p 3.
7. 7.↵
   1. Schroeder A. C.

   Leachables and Extractables in OINDP: An FDA Perspective. Presented at the PQRI Leachables and Extractables Workshop, Bethesda, MD, 2005.
8. 8.↵
   Product Quality Research Institute (PQRI), Leachables and Extractables Working Group. Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products; Product Quality Research Institute: Arlington, VA, 2006.
9. 9.↵
   1. Norwood D. L.,
   2. Prime D.,
   3. Downey B. P.,
   4. Creasey J.,
   5. Sethi S. K.,
   6. Haywood P.

   Analysis of polycyclic aromatic hydrocarbons in metered dose inhaler drug formulations by isotope dilution gas chromatography/mass spectrometry. J. Pharm. Biomed. Anal. 1995, 13 (3), 293–304.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Norwood D. L.,
    2. Mullis J. O.

    Special case leachables: a brief review. Am. Pharm. Rev. 2009, 12 (3), 78.

    OpenUrl
11. 11.↵
    1. Norwood D. L.,
    2. Mullis J. O.,
    3. Feinberg T. N.,
    4. Davis L. K.

    N-nitrosamines as “special case” leachables in a metered dose inhaler drug product. PDA J. Pharm. Sci. Technol. 2009, 63 (4), 307–321.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry—Container Closure Systems for Packaging Human Drugs and Biologics, 1999.
13. 13.↵
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDER). Draft Guidance for Industry—Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products, 1998.
14. 14.↵
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry—Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry, Manufacturing, and Controls Documentation, 2002.
15. 15.↵
    Inhalation Technology Focus Group/International Pharmaceutical Aerosol Consortium on Regulation and Science Leachables and Extractables Technical Team. Leachables and Extractables Testing: Points to Consider, 2001.
16. 16.↵
    Product Quality Research Institute (PQRI), Leachables and Extractables Working Group. PQRI Leachables and Extractables Workshop, Bethesda, Maryland, December 5–6, 2005.
17. 17.↵
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q3B (R2): Impurities in New Drug Products, ICH Harmonised Tripartaite Guideline, 2006.
18. 18.↵
    1. Ball D.,
    2. Blanchard J.,
    3. Jacobson-Kram D.,
    4. McClellan R.,
    5. McGovern T.,
    6. Norwood D. L.,
    7. Vogel M.,
    8. Wolff R.,
    9. Nagao L.

    Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Toxicol. Sci. 2007, 97 (2), 226–236.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Norwood D. L.,
    2. Paskiet D.,
    3. Ruberto M.,
    4. Feinberg T.,
    5. Schroeder A.,
    6. Poochikian G.,
    7. Wang Q.,
    8. Deng T. J.,
    9. DeGrazio F.,
    10. Munos M. K.,
    11. Nagao L. M.

    Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations. Pharm. Res. 2008, 25 (4), 727–739.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
21. 21.↵
    1. Peri P.

    Regulatory Perspectives on Extractables and Leachables. Presented at the PQRI Workshop on Safety Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products, Bethesda, MD, 2011.
22. 22.↵
    1. Harapanhalli R.

    FDA/ONDQA perspective on current requirements for extractables and leachables in the submissions, PDA 2007 Extractables and Leachables Forum, Bethesda, MD, 2007.
23. 23.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Nicholas K.

    Chapter 9. The Application of the Safety Thresholds To Qualify Leachables from Plastic Container Closure Systems Intended for Pharmaceutical Products: A Regulatory Perspective. In Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
24. 24.↵
    International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). IPAC-RS Leachables and Extractables Workshop, Rockville, MD, March 30, 2011.
25. 25.↵
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health (CDRH). Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators, 1993.
26. 26.↵
    Health Canada. Guidance for Industry. Pharmaceutical Quality of Inhalation and Nasal Products, 2006.
27. 27.↵
    European Medicines Agency. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products, 2006.
28. 28.↵
    Chapter 3. Materials and Containers. European Pharmacopoeia (EP), 6th Ed.; 2008.
29. 29.↵
    Chapter ↽ Physicochemical Tests—Plastics. United States Pharmacopoeia (USP) 34; 2011.
30. 30.↵
    ISO 10993-1. Biological evaluation of medical devices. Part 1: Evaluation and testing in the risk management process, 2009.
31. 31.↵
    European Medicines Agency. Guideline on Plastic Immediate Packaging Materials, 2005.
32. 32.↵
    European Commission. Commission Regulation (EU) No 10/2011 of 14 January 2011 on plastic materials and articles intended to come into contact with food. Off. J. Eur. Comm. L 2011, 12 (1).
33. 33.↵
    International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). GMP Guideline for Suppliers of OINDP Components; IPAC-RS: Washington, DC, 2006. New version incorporated into PS 9000: 2011 (Pharmaceutical Quality Group/IPAC-RS), September 2011.
34. 34.↵
    International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). Baseline Requirements for Materials Used in Orally Inhaled and Nasal Drug Products (OINDP); IPAC-RS: Washington, DC, 2011; available at http://www.ipacrs.com/PDFs/Baseline.pdf.
35. 35.↵
    U.S. Department of Health and Human Services, Food and Drug Administration. Pharmaceutical Quality for the 21^st Century: A Risk-based Approach; 2009; available at http://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/questionsandanswersoncurrentgoodmanufacturingpracticescgmpfordrugs/ucm071836.
36. 36.↵
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q8 (R2): Pharmaceutical Development; ICH Harmonised Tripartaite Guideline, 2009.
37. 37.↵
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q9: Quality Risk Management; ICH Harmonised Tripartaite Guideline, 2005.
38. 38.↵
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q10: Pharmaceutical Quality System; ICH Harmonised Tripartaite Guideline, 2008.
39. 39.↵
    Extractables & Leachables USA 2012 Conference Proceedings; SmithersRapra/PIRA, May 16–17, Baltimore, MD.
40. 40.↵
    Extractables and Leachables Safety Information Exchange (ELSIE). http://www.elsiedata.org/.
41. 41.↵
    1. Jenke D.

    Compatibility of Pharmaceutical Products and Contact Materials; John Wiley & Sons, Inc.: Hoboken, NJ, 2009.
42. 42.↵
    1. Laschi A.,
    2. Sehnal N.,
    3. Alarcon A.,
    4. Barcelo B.,
    5. Caire-Maurisier F.,
    6. Delaire M.,
    7. Feuilloley M.,
    8. Genot S.,
    9. Lacaze C.,
    10. Pisarik L.,
    11. Smati C.

    Container-content compatibility studies: a pharmaceutical team's integrated approach. PDA J. Pharm. Sci. Technol., 2009, 63 (4), 285–293.

    OpenUrlAbstract/FREE Full Text
43. 43.↵
    Extractables and Leachables Subcommittee of the Bio-Process Systems Alliance. Recommendations for extractables and leachables testing. Part 1: Introduction, regulatory, and risk assessment. Bioprocess Int. 2007, 5 (11), 36–44.

    OpenUrl
44. 44.↵
    Product Quality Research Institute (PQRI) PODP Working Group. PQRI Workshop on Safety Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products, Bethesda, MD, February 22–23, 2011.
45. 45.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Jacobson-Kram D.,
    2. Snyder R.

    Chapter 3. Concept and Application of Safety Thresholds in Drug Development. In Leachables and Extractables Handbook. Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
46. 46.↵
    1. Kroes R.,
    2. Renwick A.,
    3. Cheeseman M.,
    4. Kleiner J.,
    5. Mangelsdorf I.,
    6. Piersma A.,
    7. Schilter B.,
    8. Schlatter J.,
    9. van Schothorst F.,
    10. Vos J.,
    11. Würtzen G.

    Structure-based threshold of toxicological concern (TTC): Guidance for application to substances present at low levels in the diet. Food. Chem. Toxicol. 2004, 42 (1), 65–83.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.↵
    European Medicines Agency. CPMP/SWP/5199/02. Committee for Medicinal Products for Human Use. Guideline on the Limits of Genotoxic Impurities, 2006.
48. 48.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Vogel M.

    Chapter 4. The Development of Safety Thresholds for Leachables in Orally Inhaled and Nasal Drug Products. In Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
49. 49.↵
    U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDER). Draft Guidance for Industry—Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches, 1999.
50. 50.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Norwood D.,
    2. Mullis J.,
    3. Pennino S.

    Chapter 5. The Analytical Evaluation Threshold (AET) and Its Relationship to Safety Thresholds. In Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
51. 51.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Norwood D.,
    2. Stults C.,
    3. Nagao L.

    Chapter 10. Analytical Best Practices for the Evaluation and Management of Extractables and Leachables in Orally Inhaled and Nasal Drug Products. In Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
52. 52.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Norwood D.,
    2. Qiu F.,
    3. Coleman J.,
    4. Mullis J.,
    5. Granger A.,
    6. McKellop K.,
    7. Raiker M.,
    8. Robson J.

    Chapter 15. Extractables: Case Study of a Sulfur-Cured Elastomer. In Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
53. 53.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Paskiet D.,
    2. Stubbs L.,
    3. Hendriker A.

    Chapter 16. Case Study of a Polypropylene: Extractables Characterization, Quantitation, and Control. In Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
54. 54.↵
    1. Ball D. L.,
    2. Norwood D. L.,
    3. Stults C. L. M.,
    4. Nagao L. M.

    1. Feinberg T.,
    2. Norwood D.,
    3. Granger A.,
    4. Jenke D.

    Chapter 14. Extractables: The Controlled Extraction Study. In Leachables and Extractables Handbook, Ball D. L., Norwood D. L., Stults C. L. M., Nagao L. M., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, 2012.
55. 55.↵
    1. Mullis J.,
    2. Granger A.,
    3. Qin C.,
    4. Norwood D.

    The analytical evaluation threshold (AET) concept: Sensitivity and analytical uncertainty. Leachables and Extractables 2008, 2008.
56. 56.↵
    1. Jenke D.,
    2. Odufu A.

    Utilization of internal standard response factors to estimate the concentration of organic compounds leached from pharmaceutical packaging systems and application of such estimated concentrations to safety assessment. J. Chromatogr. Sci. 2012, 50 (3), 206–212.

    OpenUrlAbstract/FREE Full Text
57. 57.↵
    1. Jenke D.

    A general strategy for the chemical aspects of the safety assessment of extractables and leachables in pharmaceutical drug products: the chemical assessment triad. PDA J. Pharm. Sci. and TechNOL, 2012, 66 (2), 168–183.

    OpenUrl
58. 58.↵
    1. Markovic I.

    Challenges associated with extractables and/or leachable substances in therapeutic biological protein products. Am. Pharm. Rev. 2006, 9 (6), 20–27.

    OpenUrl
59. 59.↵
    1. Markovic I.

    Risk management strategies for safety qualification of extractables and leachable substances in therapeutic biological protein products. Am. Pharm. Rev. 2009, 12 (4), 96.

    OpenUrl